Vertex Pharmaceuticals Secures Future Pipeline with $4.9 Billion Alpine Immune Sciences Acquisition
Published on 09/18/2025 at 08:45 | Redaktion boerse-global.deThe biotechnology landscape witnessed a significant consolidation in the second quarter of 2024 as Vertex Pharmaceuticals Incorporated finalized its acquisition of Alpine Immune Sciences, Inc. The all-cash transaction, valued at approximately $4.9 billion, concluded the independent journey of the promising biotech firm, which is now a wholly-owned subsidiary of the pharmaceutical giant.
Vertex?s decision to purchase Alpine for $65 per share in cash, a deal unanimously approved by both companies’ boards of directors, underscores a clear strategic pivot. This acquisition represents a major commitment to expanding Vertex?s presence in the immunology space, a sector with substantial growth potential. Following the announcement, Alpine?s share price experienced a significant surge, rapidly converging toward the $65 offer price and effectively ending its tenure as a... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
